David P Burgner

Sep 4, 2023 | nature.com | David P Burgner

Multisystem inflammatory syndrome in children (MIS-C) is a relatively rare, but potentially life-threatening, post-infectious phenomenon, with an incidence of 2 per 100,000 SARS-CoV-2 persons younger than 21 years previously infected with SARS-CoV-2.1 A significant proportion of children with MIS-C undergo rapid clinical deterioration, characterised by shock, systemic inflammation, and cardiac dysfunction.2,3,4 Despite the substantial morbidity, the majority of children make a full recovery...

Mar 13, 2023 | amjmed.com | Zhen Zhou |Wei Zhang |David P Burgner |Andrew M. Tonkin

To determine the impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor use on incident sepsis and other severe infections. We searched PubMed, EMBASE, CENTRAL and ClinicalTrial.gov up to September 14, 2021 for double-blind, placebo-controlled randomized trials of alirocumab, evolocumab, or inclisiran with >100 participants in each arm and report of serious adverse events related to infection.

Feb 16, 2023 | nature.com | Christoph Saner |David P Burgner |Berit L Heitmann

Study design and participantsThe present study is based on data from participants of the Physical Activity and Nutrition in Children (PANIC) study. The PANIC study is an 8-year, single-center, controlled trial on the effects of a combined physical activity and dietary intervention on health outcomes in a general population sample of children from Kuopio, Finland (http://www.panicstudy.fi).